The landscape of development of treatment modalities and preventive measures for COVID-
19 has progressed expeditiously since the beginning of the pandemic. We included all the …

The Omicron (B. 1.1. 529) variant of the severe acute respiratory syndrome Coronavirus 2
(SARS-CoV-2) had an increased rate of spreading among the general population. Although …

Introduction Evidence on long-term associations between coronavirus disease 2019 (COVID-
19) and risks of multi-organ complications and mortality in older population is limited. This …

Abstract During March 2022 to January 2023, two Omicron waves hit Shanghai and caused
a massive number of reinfections. To better understand the incidence and clinical …

Objectives To assess the duration of viable virus shedding and polymerase chain reaction
(PCR) positivity of the SARS-CoV-2 Omicron variant in the upper respiratory tract. Methods …

Background Azvudine has clinical benefits and acceptable safety against COVID-19,
including in patients with comorbidities, but there is a lack of available data for its use in …

Numerous emerging severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
Omicron subvariants have shown significant immune evasion capacity and caused a large …

Antibody therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have been
approved in many countries, with most being developed based on the original strain of …

Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with
coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of …

Importance The global COVID-19 pandemic does not appear to end in the near future.
Currently, limited data are available on the risk factors for delayed viral clearance in patients …